Abstract
In the late 1960s, a crude alcohol extract from the bark of the Pacific Yew, Taxus brevifolia L., was revealed to be cytotoxic in vitro in the National Cancer Institute screening program (1,2). That extract’s principle, taxol, was isolated and characterized in 1971 by Wani et al (1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Wani MC, Taylor HL, Wall ME, et al: Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93:2325–2327, 1971.
Douros J, Suffness M: New natural products under development at the National Cancer Institute. Recent Results Cancer Res. 76:153–175, 1981.
Fuchs DA, Johnson RK: Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia. acts as a mitotic spindle poison. Cancer Treat. Rep. 62:1219–1222, 1978.
Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 22:665–667, 1979.
Schiff PB, Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. (USA) 77:1561–1565, 1980.
Rowinsky EK, Cazenave LA, Donehower RC: Taxol: A novel investigational antimicrotubule agent. J. Natl. Cancer Inst. 82:1247–1259, 1989.
Colin M, Guenard D, Gueritte-Voegelein F, Potier P: Process for preparing derivatives of baccatin III and of 10-deacetyl baccatin III. US Patent No. 4924012, granted 5/8/1990.
Denis JN, Greene AE, Guenard D, et al: A highly efficient, practical approach to natural taxol. J. Am. Chem. Soc. 110:5917–5919, 1988.
Ringel I, Horwitz SB: Studies with RP 56976 (Taxotere): A semi-synthetic analog of taxol. J. Natl. Cancer Inst. 83:288–291, 1991.
Barasoain I, De Ines C, Diaz F, et al: Interaction of tubulin and cellular microtubules with Taxotere (RP 56976), a new semisynthetic analog of taxol. Proc. Am. Assoc. Cancer Res. 32:329, 1991.
Gueritte-Voegelein F, Guenard D, Lavelle F, et al: Relationships between the structure of taxol analogues and their antimitotic activity. J. Med. Chem. 34:992–998, 1991.
Peyrot V, Briand C: Biophysical characterization of the assembly of purified tubulin induced by taxol and Taxotere (RP 56976). Second Interface of Clinical and Laboratory Responses to Anticancer Drugs: Drugs and Microtubules, Marseille, France, Abstract S22, 1992.
Rhone-Poulenc Rorer: Investigators’ Brochure RP56976. International Registration Department, Antony, France, 1992.
Lavelle F, Fizames C, Gueritte-Voegelein F, et al: Experimental properties of RP 56976, a taxol derivative. Proc. Am. Assoc. Cancer Res. 30:2254, 1989.
Riou JF, Naudin A, Lavelle F: Effects of Taxotere on murine and human tumor cell lines. Biochem. Biophys. Res. Comm. 187:164–170, 1992.
Hill BT, Whelan RDH, Shellard SA, et al: Differential cytotoxic effects of Taxotere in a range of mammalian tumour cell lines in vitro. 7th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, Abstract 247, 1992.
Bissery MC, Renard A, Montay G, et al: Taxotere: Antitumor activity and pharmacokinectics in mice. Proc. Am. Assoc. Cancer Res. 32:401, 1991.
Kelland LR, Abel G: Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother. Pharmacol. 30:444–450, 1992.
Aapro M, Braakhuis B, Dietel M, et al: Superior activity of Taxotere (Ter) over taxol (tol) in vitro. Proc. Am. Assoc. Cancer Res. 33:3086, 1992.
Hanauske AR, Degen D, Hilsensbeck SG, et al: Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 3:121–124, 1992.
Alberts DS, Garcia D, Fanta P, et al: Comparative cytotoxicities of taxol and Taxotere in vitro against fresh human ovarian cancers. Proc. ASCO 11:719, 1992.
Bissery MC, Bayssas M, Lavelle F: Preclinical evaluation of intravenous Taxotere (RP 5697 6, NSC 62-8503), a taxol analog. Proc. Am. Assoc. Cancer Res. 31:417, 1990.
Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F: Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 51:4845–4852, 1991.
Harrison SD, Dykes DJ, Shepherd RV, Bissery MC: Response of human tumour xenografts to Taxotere. Proc. Am. Assoc. Cancer Res. 33:526, 1992.
Nicoletti MI, Massazza G, Abbott BJ, et al: Taxol and Taxotere antitumor activity on human ovarian carcinoma xenografts. Proc. Am. Assoc. Cancer Res. 33:519, 1992.
Bissery MC, Renard A, Andre S, et al: Preclinical pharmacology and toxicology of Taxotere (RP 56976, NSC 628503). Ann. Oncology, Supplement 1:121, 1992.
Extra JM, Rousseau F, Bournis J, et al: Phase I trial of Taxotere (RP56976, NSC 628503). Proc. Am. Assoc. Cancer Res. 32:1225, 1991.
Extra JM, Rousseau F, Bruno R, et al: Phase I and pharmacokinetic study of Taxotere (RP 56976: NSC 628503) given as a short intravenous infusion. Cancer Res. 53:1037–1042, 1993.
Bruno R, Vergniol JC, Montay G, et al: Clinical pharmacology of Taxotere (RP56976) given as a 1-2 hour infusion every 2-3 weeks. Proc. Am. Assoc. Cancer Res. 33:261, 1992.
Tomiak E, Piccart MJ, Kerger J, et al: A Phase I study of Taxotere (RP56976, NSC 628503) adminis tered as a one hour intravenous (i.v.) infusion on a weekly basis. Eur. J. Cancer 27, Supplement 2:1–184, 1991.
DeValeriola D, Brassinne C, Piccart M, et al: Phase I pharmacokinetic study of Taxotere (RP56976) administered as a weekly infusion. Proc. Am. Assoc. Cancer Res. 33:1563, 1992.
Burris H, Irvin R, Kuhn J, et al: A phase I clinical trial of Taxotere as a 6-hour infusion repeated every 21 days in patients with refractory solid tumors. Proc. ASCO 11:137, 1992.
Irvin RJ, Burris H, Eckardt J, et al: Pharmacokinetics of a 6 hr Taxotere infusion (RP56976, NSC 628503). Proc. ASCO 11:108, 1992.
Burris HA, Irvin RJ, Kuhn J, et al: A Phase I clinical trial with Taxotere administered as a six hour or two hour infusion repeated every twenty-one days in patients with refractory solid tumors. J. Clin. Oncol, in press.
Bissett D, Setanoians A, Cassidy J, et al: Phase I and pharmacokinetic study of Taxotere (RP56976) administered as a 24-hour infusion. Cancer Res. 53:523–527, 1993.
Pazdur R, Newman RA, Newman BM, et al: Phase I trial of Taxotere: Five-day schedule. J. Natl. Cancer Inst. 84:1781–1788, 1992.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bissery, MC., Burris, H., Pazdur, R. (1994). Preclinical Pharmacology and Phase I Clinical Trials of TaxotereR (RP 56976, NSC 628503). In: Valeriote, F.A., Corbett, T.H., Baker, L.H. (eds) Anticancer Drug Discovery and Development: Natural Products and New Molecular Models. Developments in Oncology, vol 74. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2610-0_14
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2610-0_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6118-3
Online ISBN: 978-1-4615-2610-0
eBook Packages: Springer Book Archive